ACADIA Pharmaceuticals

ACADIA is a leading biopharmaceutical company dedicated to the development and commercialization of innovative medicines that improve the lives of patients with central nervous system disorders. ACADIA has ongoing clinical development efforts in areas with significant unmet needs, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome. More information about ACADIA, our current commercialized product, and our clinical development programs can be found at: